Bizarre Patents
Behavior Modification Wristwatch
A wristwatch including a watch band and a watch body having an octagon shaped perimeter and being red in color and having the word STOP thereon to resemble a stop sign.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187874 | Drug discovery method The present invention relates to drug discovery methods, particularly antiviral drug discovery methods. ... | 05/29/2012 |
| 7919314 | Process for the production of monoclonal antibodies Provided is a use of a recombinant chimaeric protein as an immunogen in a process for producing a monoclonal antibody, wherein the recombinant chimaeric protein is assembled into a virus-like particles, and includes a foreign protein or peptide or a fragment thereof... | 04/05/2011 |
| 7385049 | Oligonucleotides and methods for detection of West Nile virus The invention provides methods of detecting West Nile virus and oligonucleotide reagents derived from a West Nile virus consensus sequence that are useful in the methods of the invention. ... | 06/10/2008 |
| 7345152 | Monoclonal antibody specific for an epitope of inactivated feline immunodeficiency-encoded glycoprotein The present invention provides a monoclonal antibody specific for an epitope which is unique to the surface protein component of an inactivated feline immunodeficiency virus (FIV) envelope glycoprotein. Said antibody is useful for the quantification of inactivated F... | 03/18/2008 |
| 7341870 | Dendritic cell line The invention relates to plasmacytoid dendritic human cell lines and methods for producing the cell lines. More specifically, the invention relates to the plasmacytoid dendritic human cell line called GEN2.2, which is deposited in the CNCM under number CNCM 1-2938 a... | 03/11/2008 |
| 7332162 | Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders A ligand derived from, e.g. a Fab fragment of, a monoclonal antibody obtainable from the cell line deposited with the Belgian Coordinated Collections of Micro-organisms under accession number LMBP 5108CB binds to the human platelet glycoprotein GPib and prevents the... | 02/19/2008 |
| 7332269 | HCV core protein sequences The present invention describes peptides and recombinant proteins containing Hepatitis C virus core protein sequence in which one or more of the amino acids have been modified or deleted to remove the ability of these proteins to bind to specific anti-HCV murine mon... | 02/19/2008 |
| 7323331 | Method for detecting or assaying HBV A Method for detecting hepatitis B virus as well as a kit and a reagent therefor, comprising using a phosphate buffer that specifically binds to hepatitis B virus, for example a monoclonal antibody that specifically binds to a specific site of core-related protein o... | 01/29/2008 |
| RE39586 | Human monoclonal antibody against Hepatitis B virus surface antigen (HBVSAG) Disclosed is a hybridoma cell line which produces human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as antibodies produced by the cell line. Also disclosed are various uses of said antibodies in the prevention and treatme... | 04/24/2007 |
| 7176021 | Mutant cells with altered sialic acid The invention provides cells useful to propagate influenza virus mutants having reduced sialidase activity. ... | 02/13/2007 |
| 7105303 | Antibodies to hepatitis C virus asialoglycoproteins Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more simi... | 09/12/2006 |
| 7071319 | Recombinant antibodies, and compositions and methods for making and using the same Recombinant antibodies are disclosed. The nucleic acid and encoded amino acid sequences of the heavy and light chain immunoglobulins of human monoclonal rabies virus neutralizing antibodies, and their use, are described. ... | 07/04/2006 |
| 7049060 | HCV anti-core monoclonal antibodies Monoclonal antibodies that specifically bind to HCV core antigen. Also provided are hybridoma cell lines which secrete these antibodies, methods for making and using these antibodies, including kits that include these antibodies. ... | 05/23/2006 |
| 7041293 | HIV env antibodies The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/g120 binding and reduce reverse transcriptase activity in vitro. ... | 05/09/2006 |
| 7026457 | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recombinantly ex... | 04/11/2006 |
| 6949628 | ANTICYTOMEGALOVIRUS MONOCLONAL ANTIBODIES AND PROCESSES FOR THE IN VITRO DIAGNOSIS OF INFECTIONS BY HUMAN CYTOMEGALOVIRUSES AND A PROTEIN-KINASE INDUCIBLE BY CYTOMEGALOVIRUSES AND RECOGNIZABLE BY AFORESAID MONOCLONAL ANTIBODIES The invention relates to a process for in vitro diagnosis of an infection by human cytomegaloviruses. The process consists of contacting cells, possibly carrying the infection, with a monoclonal antibody reacting with a polypeptide of molecular weight 68,000, induce... | 09/27/2005 |
| 6927031 | Methods for identifying polypeptide factors interacting with RNA The present invention relates to methods of screening for target polypeptides that bind to RNA, using affinity purification methods, and the use of such target polypeptide for drug discovery and in methods of treating and preventing disease, e.g., HCV infection.... | 08/09/2005 |
| 6818392 | Monoclonal antibodies to human immunodeficiency virus and uses thereof The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared... | 11/16/2004 |
| 6812329 | Construction and characterization of monoclonal antibodies against western equine encephalitis virus Construction and characterization of mouse monoclonal antibodies against western equine encephalitis virus (WEE) for potential use in detection, diagnosis, and immunotherapy are disclosed. Antibodies were prepared from hybridoma cells and further characterized by EL... | 11/02/2004 |
| 6803035 | Anti-diarrheal and method for using the same A food product and method for treating and preventing diarrhea in a subject animal suffering from or susceptible to diarrhea. The method comprises administering an egg product to the subject animal wherein the egg product is obtained from a hyperimmunized avian.... | 10/12/2004 |
| 6727059 | METHOD FOR CONTROLLING THE FIDELITY AND PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATION AND POLYMERIZATION OF NUCLEOTIDE ANALOGS ACCEPTED AS SUBSTRATES FOR THE REVERSE TRANSCRIPTION REACTION WITHOUT BLOCKING ITS ELONGATION The invention concerns the use of nucleotide analogues, defined as molecules acceptable as substrate of the reverse-transcription response and enabling the addition of at least one supplementary nucleotide to the polynucleotide chain during synthesis to affect and/o... | 04/27/2004 |
| 6692908 | Prevention and treatment of HCV infection employing antibodies that inhibit the interaction of HCV virions with their receptor Human monoclonal antibodies binding to epitopes common to type 1 and 2 HCV are provided, as well as conformationally conserved HCV E2 2a and 2b proteins. Compositions comprising the antibodies find use in diagnosis and therapy. The antibodies recognize co... | 02/17/2004 |
| 6682909 | Immunogenic composition of hepatitis C and methods of use thereof The present invention provides truncated HCV E2 polypepides. The invention HCV E2 polypeptides lack the HVR1 region that provides immune protection against HCV. The present invention also provides immunogenic compositions of such polypeptides and the meth... | 01/27/2004 |
| 6596268 | Viruses for the treatment of cellular proliferative disorders Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pa... | 07/22/2003 |
| 6557296 | Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor This invention is directed toward mutated DNA, proteins, or protein fragments and particles from the L-2 cell line. The invention is also directed to diagnostic, prophylactic and therapeutic methods of making and using the DNA, proteins and particles.... | 05/06/2003 |
| 6541253 | Diagnostics and therapy of diseases associated with HHV-8 infections The present invention is directed to monoclonal antibodies capable of specifically binding to and recognizing an antigenic determinant (epitope) of the protein kaposin or a derivative thereof, hybridoma cell lines producing said monoclonal antibodies, dia... | 04/01/2003 |
| 6541198 | Antibodies and other binding molecules specific for hepatitis B viral antigens The present invention relates to antibodies and other binding molecules specific for hepatitis B viral antigens (HBV), peptides comprising epitopes recognized by such molecules, and cell lines capable of producing antibodies. The invention is further conc... | 04/01/2003 |
| 6541223 | Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins A method for increasing production yield of viruses, viral proteins, and other related biological materials through enhanced control and stabilization of protein production via stress proteins and the resultant protein products. The present invention is a... | 04/01/2003 |
| 6538126 | Hepatitis C diagnostics and vaccines The present invention provides polynucleotides derived from cDNA of novel type of hepatitis C virus named Korean type hepatitis C virus (KHCV), polypeptides encoded therein, and antibodies directed against the polypeptides; and also provide diagnostics an... | 03/25/2003 |
| 6537809 | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro primary of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human... | 03/25/2003 |
| 6534312 | Vaccines comprising synthetic genes Synthetic polynucleotides comprising a DNA sequence encoding a peptide or protein are provided. The DNA sequence of the synthetic polynucleotides comprise codons optimized for expression in a nonhomologous host. The invention is exemplified by synthetic D... | 03/18/2003 |
| 6528252 | Methods for identifying a protease inhibitor Methods are disclosed whereby inhibition of proteolytic activity causes an increase in delivery of a transferable label from a viral display package to a target cell. Assaying for the transferable label in the target cell in the presence of a test substan... | 03/04/2003 |
| 6506557 | Methods and compositions for identifying a protease Methods are disclosed whereby protease activity is directly linked to replication of viral display packages containing protease-encoding polynucleotides in target cells. The methods can be used, inter alia, to identify proteases, including previously undi... | 01/14/2003 |
| 6503753 | Method for the development of an HIV vaccine Human immunodeficiency virus (HIV) comprising reverse transcriptase inactivated by photoinactivation. The inactivated virus may be more safely handled, stored, and analyzed, used in diagnostic procedures and kits, and may be used as an immunogen to evoke ... | 01/07/2003 |
| 6492165 | Retrovirus isolated from humans The present invention comprises spumavirus isolated from humans. More specifically, the spumavirus of the present invention was isolated from humans who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies ... | 12/10/2002 |
| 6471962 | Monoclonal antibodies for infectious bursal disease, vaccines and assays for use therewith Two monoclonal antibodies which neutralize all infectious bursal disease viruses are employed in the preparation of infectious bursal disease vaccines. A panel of monoclonal antibodies can be used to characterize the infectious bursal disease virus strain... | 10/29/2002 |
| 6465173 | Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods ... | 10/15/2002 |
| 6455264 | Antibodies and diagnostic methods for the diagnosis of pestiviruses The present invention relates to a diagnostic method for the diagnosis of Pestivirus infection in animals, in particular to a method for the diagnosis of animals infected with BVDV. A monoclonal antibody directed to a conserved antigen determinant on the ... | 09/24/2002 |
| 6440659 | Inhibitors of retroviral protease as inducers of reversible insulin resistance in vitro and in vivo This invention provides novel assays for measuring the metabolic side-effects of antiretroviral protease inhibitors on the Glut4 glucose transporter. The invention also provides improved methods for developing antiretroviral protease drugs, particularly t... | 08/27/2002 |
| 6423539 | Adjuvant treatment by in vivo activation of dendritic cells The immunogenicity of an antigen is enhanced by increasing the specific antigen presenting function of dendritic cells (DC) in a mammalian host. The host is treated with a DC mobilization agent to increase the number of circulating DC precursors. The host... | 07/23/2002 |
